Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 107

1.

A randomized trial of relamorelin for constipation in Parkinson's disease (MOVE-PD): Trial results and lessons learned.

Parkinson Study Group. Electronic address: pfeiffro@ohsu.edu..

Parkinsonism Relat Disord. 2017 Apr;37:101-105. doi: 10.1016/j.parkreldis.2017.02.003. Epub 2017 Feb 14.

PMID:
28237854
2.

Metabolomic biomarkers as strong correlates of Parkinson disease progression.

LeWitt PA, Li J, Lu M, Guo L, Auinger P; Parkinson Study Group–DATATOP Investigators..

Neurology. 2017 Feb 28;88(9):862-869. doi: 10.1212/WNL.0000000000003663. Epub 2017 Feb 8.

PMID:
28179471
3.

Orthostatic hypotension predicts motor decline in early Parkinson disease.

Kotagal V, Lineback C, Bohnen NI, Albin RL; CALM-PD Parkinson Study Group Investigators..

Parkinsonism Relat Disord. 2016 Nov;32:127-129. doi: 10.1016/j.parkreldis.2016.09.011. Epub 2016 Sep 9.

PMID:
27639815
4.

Randomized, controlled pilot trial of solifenacin succinate for overactive bladder in Parkinson's disease.

Zesiewicz TA, Evatt M, Vaughan CP, Jahan I, Singer C, Ordorica R, Salemi JL, Shaw JD, Sullivan KL; Non-Motor Working Group of the Parkinson Study Group (PSG)..

Parkinsonism Relat Disord. 2015 May;21(5):514-20. doi: 10.1016/j.parkreldis.2015.02.025. Epub 2015 Mar 6.

PMID:
25814050
5.

CSF tau and tau/Aβ42 predict cognitive decline in Parkinson's disease.

Liu C, Cholerton B, Shi M, Ginghina C, Cain KC, Auinger P; Parkinson Study Group DATATOP Investigators., Zhang J.

Parkinsonism Relat Disord. 2015 Mar;21(3):271-6. doi: 10.1016/j.parkreldis.2014.12.027. Epub 2015 Jan 5.

6.

Mendelian randomization of serum urate and parkinson disease progression.

Simon KC, Eberly S, Gao X, Oakes D, Tanner CM, Shoulson I, Fahn S, Schwarzschild MA, Ascherio A; Parkinson Study Group..

Ann Neurol. 2014 Dec;76(6):862-8. doi: 10.1002/ana.24281. Epub 2014 Oct 3.

7.

Impact of disclosure of individual imaging results in a multi-center Parkinson clinical trial.

Jennings D, Eberly S, Oakes D, Seibyl J, Marek K, Shoulson I; Parkinson Study Group PRECEPT Investigators..

J Parkinsons Dis. 2014;4(4):629-38. doi: 10.3233/JPD-140383.

PMID:
25062961
8.

Association of Catechol-O-Methyltransferase and monoamine oxidase B gene polymorphisms with motor complications in parkinson's disease in a Chinese population.

Hao H, Shao M, An J, Chen C, Feng X, Xie S, Gu Z, Chan P; Chinese Parkinson Study Group..

Parkinsonism Relat Disord. 2014 Oct;20(10):1041-5. doi: 10.1016/j.parkreldis.2014.06.021. Epub 2014 Jul 4. Review.

PMID:
25034874
9.

Urate and neuroprotection trials.

Schwarzschild MA, Macklin EA, Ascherio A; Parkinson Study Group SURE-PD Investigators..

Lancet Neurol. 2014 Aug;13(8):758. doi: 10.1016/S1474-4422(14)70138-3. No abstract available.

PMID:
25030508
10.

Gender differences on motor and non-motor symptoms of de novo patients with early Parkinson's disease.

Song Y, Gu Z, An J, Chan P; Chinese Parkinson Study Group..

Neurol Sci. 2014 Dec;35(12):1991-6. doi: 10.1007/s10072-014-1879-1. Epub 2014 Jul 11.

PMID:
25012756
11.

Clinical characteristics of Parkinson's disease patients in Greece: a multicenter, nation-wide, cross-sectional study.

Konitsiotis S, Bostantjopoulou S, Chondrogiorgi M, Katsarou Z, Tagaris G, Mavromatis I, Ntzani EE, Mentenopoulos G; members of the Greek Parkinson Study Group..

J Neurol Sci. 2014 Aug 15;343(1-2):36-40. doi: 10.1016/j.jns.2014.05.003. Epub 2014 May 11.

PMID:
24950902
12.

Longitudinal follow-up of SWEDD subjects in the PRECEPT Study.

Marek K, Seibyl J, Eberly S, Oakes D, Shoulson I, Lang AE, Hyson C, Jennings D; Parkinson Study Group PRECEPT Investigators..

Neurology. 2014 May 20;82(20):1791-7. doi: 10.1212/WNL.0000000000000424. Epub 2014 Apr 23.

13.

A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit.

Parkinson Study Group QE3 Investigators., Beal MF, Oakes D, Shoulson I, Henchcliffe C, Galpern WR, Haas R, Juncos JL, Nutt JG, Voss TS, Ravina B, Shults CM, Helles K, Snively V, Lew MF, Griebner B, Watts A, Gao S, Pourcher E, Bond L, Kompoliti K, Agarwal P, Sia C, Jog M, Cole L, Sultana M, Kurlan R, Richard I, Deeley C, Waters CH, Figueroa A, Arkun A, Brodsky M, Ondo WG, Hunter CB, Jimenez-Shahed J, Palao A, Miyasaki JM, So J, Tetrud J, Reys L, Smith K, Singer C, Blenke A, Russell DS, Cotto C, Friedman JH, Lannon M, Zhang L, Drasby E, Kumar R, Subramanian T, Ford DS, Grimes DA, Cote D, Conway J, Siderowf AD, Evatt ML, Sommerfeld B, Lieberman AN, Okun MS, Rodriguez RL, Merritt S, Swartz CL, Martin WR, King P, Stover N, Guthrie S, Watts RL, Ahmed A, Fernandez HH, Winters A, Mari Z, Dawson TM, Dunlop B, Feigin AS, Shannon B, Nirenberg MJ, Ogg M, Ellias SA, Thomas CA, Frei K, Bodis-Wollner I, Glazman S, Mayer T, Hauser RA, Pahwa R, Langhammer A, Ranawaya R, Derwent L, Sethi KD, Farrow B, Prakash R, Litvan I, Robinson A, Sahay A, Gartner M, Hinson VK, Markind S, Pelikan M, Perlmutter JS, Hartlein J, Molho E, Evans S, Adler CH, Duffy A, Lind M, Elmer L, Davis K, Spears J, Wilson S, Leehey MA, Hermanowicz N, Niswonger S, Shill HA, Obradov S, Rajput A, Cowper M, Lessig S, Song D, Fontaine D, Zadikoff C, Williams K, Blindauer KA, Bergholte J, Propsom CS, Stacy MA, Field J, Mihaila D, Chilton M, Uc EY, Sieren J, Simon DK, Kraics L, Silver A, Boyd JT, Hamill RW, Ingvoldstad C, Young J, Thomas K, Kostyk SK, Wojcieszek J, Pfeiffer RF, Panisset M, Beland M, Reich SG, Cines M, Zappala N, Rivest J, Zweig R, Lumina LP, Hilliard CL, Grill S, Kellermann M, Tuite P, Rolandelli S, Kang UJ, Young J, Rao J, Cook MM, Severt L, Boyar K.

JAMA Neurol. 2014 May;71(5):543-52. doi: 10.1001/jamaneurol.2014.131.

PMID:
24664227
14.

Cerebrospinal fluid α-synuclein predicts cognitive decline in Parkinson disease progression in the DATATOP cohort.

Stewart T, Liu C, Ginghina C, Cain KC, Auinger P, Cholerton B, Shi M, Zhang J; Parkinson Study Group DATATOP Investigators..

Am J Pathol. 2014 Apr;184(4):966-75. doi: 10.1016/j.ajpath.2013.12.007. Epub 2014 Mar 11.

15.

Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial.

Parkinson Study Group SURE-PD Investigators., Schwarzschild MA, Ascherio A, Beal MF, Cudkowicz ME, Curhan GC, Hare JM, Hooper DC, Kieburtz KD, Macklin EA, Oakes D, Rudolph A, Shoulson I, Tennis MK, Espay AJ, Gartner M, Hung A, Bwala G, Lenehan R, Encarnacion E, Ainslie M, Castillo R, Togasaki D, Barles G, Friedman JH, Niles L, Carter JH, Murray M, Goetz CG, Jaglin J, Ahmed A, Russell DS, Cotto C, Goudreau JL, Russell D, Parashos SA, Ede P, Saint-Hilaire MH, Thomas CA, James R, Stacy MA, Johnson J, Gauger L, Antonelle de Marcaida J, Thurlow S, Isaacson SH, Carvajal L, Rao J, Cook M, Hope-Porche C, McClurg L, Grasso DL, Logan R, Orme C, Ross T, Brocht AF, Constantinescu R, Sharma S, Venuto C, Weber J, Eaton K.

JAMA Neurol. 2014 Feb;71(2):141-50. doi: 10.1001/jamaneurol.2013.5528.

16.

Phase II safety, tolerability, and dose selection study of isradipine as a potential disease-modifying intervention in early Parkinson's disease (STEADY-PD).

Parkinson Study Group..

Mov Disord. 2013 Nov;28(13):1823-31. doi: 10.1002/mds.25639. Epub 2013 Sep 30.

PMID:
24123224
17.

Clinical profiles of Parkinson's disease associated with common leucine-rich repeat kinase 2 and glucocerebrosidase genetic variants in Chinese individuals.

Wang C, Cai Y, Gu Z, Ma J, Zheng Z, Tang BS, Xu Y, Zhou Y, Feng T, Wang T, Chen SD, Chan P; Chinese Parkinson Study Group..

Neurobiol Aging. 2014 Mar;35(3):725.e1-6. doi: 10.1016/j.neurobiolaging.2013.08.012. Epub 2013 Oct 3.

PMID:
24095219
18.

Longitudinal assessment of tau and amyloid beta in cerebrospinal fluid of Parkinson disease.

Zhang J, Mattison HA, Liu C, Ginghina C, Auinger P, McDermott MP, Stewart T, Kang UJ; Parkinson Study Group DATATOP Investigators., Cain KC, Shi M.

Acta Neuropathol. 2013 Nov;126(5):671-82. doi: 10.1007/s00401-013-1121-x. Epub 2013 May 4.

19.

Caffeine consumption and risk of dyskinesia in CALM-PD.

Wills AM, Eberly S, Tennis M, Lang AE, Messing S, Togasaki D, Tanner CM, Kamp C, Chen JF, Oakes D, McDermott MP, Schwarzschild MA; Parkinson Study Group..

Mov Disord. 2013 Mar;28(3):380-3. doi: 10.1002/mds.25319. Epub 2013 Jan 21.

20.

Penetrance of LRRK2 G2385R and R1628P is modified by common PD-associated genetic variants.

Wang C, Cai Y, Zheng Z, Tang BS, Xu Y, Wang T, Ma J, Chen SD, Langston JW, Tanner CM, Chan P; Chinese Parkinson Study Group (CPSG)..

Parkinsonism Relat Disord. 2012 Sep;18(8):958-63. Epub 2012 Jun 2.

PMID:
22658533

Supplemental Content

Loading ...
Support Center